Rare Diseases Weekly News - August 14th 2025
🧬 This Week in Rare Diseases: FDA Approvals, Global Partnerships, Breakthrough…
Rare Diseases Weekly News - July 31st 2025
🧬 This Week in Rare Diseases: FDA Leadership, Gene Therapy Safety, New Drug…
EHA 2025 Preview: Key Hematology Highlights to Watch
EHA at a glance Join LucidQuest for a concise EHA 2025 preview, focusing on…
Cell and Gene Therapy Weekly News - May 29th 2025
This Week in Gene & Cell Therapy: Clinical Trial Expansions, Rare Disease…
How a pharma in the multiple myeloma space gained access to leading KOLs insights and used them in its asset development process.
The Challenge: Understanding how KOLs define the treatment evolution and the…
How we helped two pharma companies assess their own and their competitors' social media during ESMO 2023 and ASCO 2023.
The Challenge: How to maximize the benefits of social media monitoring during…
How our benchmarking analysis contributed to a Hemato-Oncology company's sales and pricing strategy for specific agents.
The Challenge: Competitive benchmarking, including sales force and market…
How a hematology brand utilized competitor sales force research to defend itself against a competitor entrant in Spain.
The Challenge: How to react to a new entrant threat A hematology brand team of…
How a pharma in the multiple myeloma space gained access to leading KOLs insights and used them in its asset development process.
The Challenge: Understanding how KOLs define the treatment evolution and the…
How a large pharma in Hematology and Oncology space established and used competitive benchmarks across the US
The Challenge: Knowing field force performance against the competition A large…
Multiple myeloma treatment: Why we still need novel scientific research.
Multiple myeloma (MM) is an incurable form of hematological cancer affecting…
